Drug Trial Radar · NCT05190575
TST001 in Patients With CLDN18.2 Positive Previously Treated Advanced Biliary Tract Cancer
Last checked: Nov 19, 2026Latest source record: Jul 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jan 14, 2022
Primary completion
May 6, 2023
Study completion May 6, 2023
Sponsor
- Lead sponsor
- Shanghai Zhongshan HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Transcenta Holding Limited
- First posted
- Jan 13, 2022
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
TST001 is a recombinant humanized anti-Claudin 18.2 (CLDN18.2) IgG1 monoclonal antibody. This is an open-label, single-arm phase II study to evaluate the efficacy and safety of TST001 for patients with CLDN18.2 positive previously treated unresectable advanced or metastatic Biliary Tract Cancer.
Conditions
- Biliary Tract Neoplasms
Interventions
TST001Drug
TST001 IV infusion every 3 weeks until disease progression or other discontinuation criteria.
Primary outcomes
What the sponsor says the trial is designed to measure.
- ORRTime frame: 18 months
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan hospital
Shanghai, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.